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pAbstract
Mitochondrial disease can be a devastating, degenerative illness, with limited
treatment and no cure. Novel reproductive techniques involving mitochondria
donation present an opportunity for women with mitochondrial disease to prevent
the transmission of disease to her offspring. Current IVF techniques, such as
pre-implantation genetic diagnosis, reduce but do not eliminate the risk for the
child. However, knowledge of the contexts within which this disease is experienced
and reproductive decisions are made is limited. This article draws on qualitative
interviews with adult patients to explore the practical realities of living with
mitochondrial disease. Three key themes were identified; the personal and familial
experiences of illness, age and generation as factors in shaping patient experience
and the importance of experiential knowledge in making sense of reproductive
choice. Overall, this article identifies potential barriers to patients accessing
reproductive technologies highlighting how the complex nature and uncertain
trajectory of mitochondrial disease poses considerable challenges for patients,
practitioners and policy makers.Introduction
This research has taken place within an evolving landscape of genetic medicine. IVF
techniques preventing the transmission of mitochondrial disease from mother to child
provide a technological solution to a disease with no cure and extremely limited treat-
ment. The process involves removing the nucleus of an egg with faulty mitochondria,
and placing it into a donated, enucleated egg containing healthy mitochondria. As
mitochondria contain DNA, these ‘germ line’ therapies are currently prohibited and a
change in law would be necessary before they can be offered to patients. The tech-
niques have attracted intense interest and speculation (Bredenoord & Braude 2010;
Sample 2012). The Human Fertilisation and Embryology Authority (HFEA) have
launched a consultation seeking the views of the public and stakeholders, the results of
which will be published in 2013.
Following a call for evidence from patients, professionals and publics, the Nuffield
Council on Bioethics recommended the provision of information and support to pa-
tients when negotiating novel reproductive techniques (Nuffield Council on Bioethics
2012). In contrast to the extensive interest in the ethical challenges presented by mito-
chondrial donation, the impact of the disease on patients and families, particularly the
adult experience of disease, has attracted much less attention and reflection. This lack2013 Dimond; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
rovided the original work is properly cited.
Dimond Life Sciences, Society and Policy 2013, 9:2 Page 2 of 11
http://www.lsspjournal.com/content/9/1/2of understanding of the adult experience is critical as it is adult women with mitochon-
drial disease who are the target population for reproductive techniques yet the needs of
these patients have yet to be articulated.
Mitochondria are small structures contained in the cytoplasm of a cell, producing en-
ergy in the form of ATP (adenosine triphosphate). Each cell contains hundreds to thou-
sands of mitochondria, depending on the energy requirements of particular tissues.
The term ‘mitochondrial disease’ was introduced in the late 1980’s to describe the im-
pact of mitochondria dysfunction, which can be due to mutations in either nuclear or
mitochondrial DNA sequences. As mitochondria are derived through the oocyte (only
one case of paternal inheritance of mitochondria DNA has been identified- Schwartz &
Vissing 2002), disease caused by mutations of mitochondrial DNA display a maternal
inheritance pattern. Both sexes can inherit the disease but it is only women who are at
risk of transmitting the disease to their children. The impact of mitochondrial disease
is extremely variable, depending on which organs are affected and to what extent.
Symptoms can include extreme fatigue, cardiomyopathy, diabetes, difficulties with mo-
bility and balance, digestive disorders, deafness, epilepsy and restricted sight. Mitochon-
drial disease is an umbrella label which encompasses a range of disorders. The
distinctions in classification and implications for clinical management are beyond the
scope of this paper and are described elsewhere (DiMauro 2011; Kisler et al. 2010). An
expansive range of symptoms and levels of severity, a complex relationship between
genotype and phenotype and the potential for changes in mutation ratio over time pre-
sents considerable difficulties for ascertaining prevalence of disease within the popula-
tion (Schaefer et al. 2008) and for diagnosis, clinical management and genetic
counselling (Brown et al. 2006; Poulton et al. 2010; Bredenoord et al. 2009).
Accounts of mitochondrial donation, in media coverage in particular, forecast that if
these techniques are made available then this will ‘halt’, ‘eliminate’ or ‘eradicate’ mito-
chondrial disease from families (see, for example Ahuja 2012). The central tenant of
this article is to question this assumption of technological determinism which is in dir-
ect contrast to the findings of this study and the wealth of sociological research
highlighting the diverse contexts within which the boundaries of health, illness, and risk
are negotiated. Three key themes are explored: the personal and familial experiences of
illness, age and generation as factors in shaping patient experience and the importance
of experiential knowledge in making sense of reproductive choice. This is the first em-
pirical study to examine how the complexity and uncertainty of mitochondrial disease
impacts on the patient experience and experiences of reproductive risk, providing a
unique contribution to an under researched yet highly topical area.
This article initiates discussion on the patient experience of mitochondrial disease. It
is based on the accounts of twenty five patients diagnosed with mitochondrial disease
caused by a mutation in mitochondrial DNA. All were contacted through a national
mitochondria research clinic. The topics discussed included the experience of diagnosis,
current and future health management, communication strategies and the role of re-
productive technologies. The semi-structured interviews were analysed according to
thematic analysis, allowing themes to emerge as the research progressed (Strauss &
Corbin 1998). Because of the specific nature of mitochondrial disease, this qualitative
research approach does not necessarily produce results that are generalisable to other
conditions, nor can it hope to represent the experience of all those with mitochondrial
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a complex, uncertain and rare genetic disorder. Ethical approval was gained through
the South Wales Ethics Committee. Extracts from the interview transcripts used in this
article have been anonymised to preserve patient confidentiality.Personal and familial experiences of illness
Through participant accounts, mitochondrial disease emerges as a highly variable gen-
etic disorder associated with a complex network of signs and symptoms evolving over
time. Pain and discomfort can become a part of normal life, and prior to diagnosis, par-
ticipants were often unaware that they were experiencing what might be classified as
‘symptoms’. One man described the muscle cramps he experienced as a child, “I’ve had
them all my life, it was something that wasn’t unusual and I just thought, you know,
that’s part of life” [no.09]. The relatively recent discovery of mitochondrial disease
meant that many respondents knew there was ‘something wrong’ long before receiving
a diagnosis. One woman’s account of diagnosis highlights how the range and evolution
of symptoms can be problematic for patients, families and professionals:
But to be quite honest, for years I thought there was something wrong with me and
I kept going to doctors saying this is wrong, that is wrong, you know, and they’d
send me for tests and I’d go back and they’d say there’s nothing wrong with you, and
in the end I stopped going to doctors because I thought I was a hypochondriac. All
these symptoms that I was getting, that I know now is the mitochondrial myopathy,
they were poo-pooing saying oh it’s in your mind. So for years I knew that there was
something wrong but then in the family, my sister was the sick one, you know, as we
were younger. I looked after my sister, I wasn’t allowed to be ill because I was
looking after my sister and I didn’t say anything because I thought well they’re only
going to say you’re jumping on the bandwagon, you want a bit of attention as well.
So you know, all these little things that were building up, I just kept them to myself
and then the doctors wouldn’t help me. So it was a big relief when I found out that
there was something wrong. It was a relief in one way but then in another way, when
I found out, they also said that my daughter would have it, so it was a double-edged
sword basically. [no.28, woman, age 59]
This single account reveals many of the complexities of the patient experience. The
expansive range of symptoms associated with the disease, differing levels of severity be-
tween members of the same family and limitations of local professional knowledge
compound the difficulties of diagnosis. The woman’s stance is indicative of deep famil-
iarity with the symptoms of disease. Many participants and their families had in fact
lived with the symptoms of mitochondrial disease a long time before the development
of diagnostic technologies, in which case, receiving a diagnosis can be a transformative
process, enabling access to a legitimate patient identity, treatment and support
(Jutel 2011).
However the diagnosis of a genetic disease can have far reaching implications, stand-
ing in marked contrast to other types of illness because of particular associations with
‘family’ (Hallowell et al. 2003). A genetic diagnosis becomes a ‘double-edged sword’
with implications for blame and responsibility. The potential impact of ‘new biological
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should not be reduced to concern about reproductive risk. Many of those interviewed
identified members of their extended family on their maternal side who were affected by
disease. Most significantly, throughout their accounts, participants did not just talk about
their own experiences of illness but about their observations and experiences of others.
Mitochondrial disease is a progressive, degenerative disorder. For some this trajectory
was experienced as a ‘creep’, as one woman described, “it just creeps up on you and it’s
something different every day” [no.15] and another described, “my health has deterio-
rated over the last couple of years, seen it sort of creeping up” [no.19]. Participants
talked about how they were vigilant for signs of disease progression, surveilling them-
selves and others for signs of illness. This mapping of disease and making comparisons
between oneself and others could be an emotional process, as one woman explained
“it’s upsetting because it’s like looking in a mirror, looking at my mother and my sister,
and my other sister, she’s in a wheelchair now” (no.05 emphasis added). This is a
process of transgenerational observation, involving the surveillance of younger and
presymptomatic members of the family. One woman described how she observed her
daughter for signs of illness, specifically checking the ability to do the tasks that she
was no longer able to do herself, “I keep looking, watching.....my daughter can kneel
down without falling over and you know different things” [no.10].
The nature of mitochondrial disease is such that symptoms and severity can differ be-
tween members of a family, which means that individuals can maintain good health
while others rapidly decline. In contrast to the slow ‘creep’ of disease, for some, the im-
plications of an uncertain illness trajectory, particularly the risk of sudden decline,
appeared significant. Mitochondrial disease was described by one participant as a
“waiting game” and a “time bomb” [no.26]. The uncertainty of disease progression and
the implications for risk to one’s own health are compounded by the difficulties of
watching a close family member suffer.
It’s difficult, I don’t know where my illness is going from one day to the next. I’ll be
honest, I don’t know whether I’ll wake up in six months’ time or whether I’ve got
20 years. The problem is once you go downhill you don’t recover, you stay at the
point you’re at and next time you go downhill, you get worse and eventually, 9 times
out of 10, your organs start packing up. I had to sit there and watch my own brother
[die] and I know it’s a possibility that may be me as well. [no.18, man, age 42]
This man’s account reveals the impact of diverse illness trajectories. Whereas mito-
chondrial disease is generally progressive, the path ‘downhill’ can be unpredictable and
impossible to map. So for this man, the fact that “you never know what’s going to hap-
pen next” [no.18] was compounded by his experience of watching his brother fall ser-
iously ill. The clues that he uses to inform his own future are his observations of
watching the decline of a close member of the family. These techniques of self and mu-
tual surveillance (Featherstone et al. 2006) are key for understanding how patients and
family members position themselves and others, and how futures are projected. During
the interviews, participants did not necessarily talk about the technical aspects of the
causes and genetic complexities of mitochondrial disease. Instead many displayed a
deep and extensive knowledge of its consequences on their own and others’ bodies,
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experience and observation, often involving several generations, highlights how the
disease can become both normalised and feared through every day practices (Forrest
et al. 2008).
Asymptomatic patients and the generation gap
There is no doubt that mitochondrial disease can be devastating and distressing. Many
participants who experienced serious symptoms or who had watched the sudden decline
of family members gave thick descriptions of living with mitochondrial disease, describing
it as “a death sentence” [no.03], “a wretched disease” [no.02], “a horrible thing to have”
[no.18] and “hard to live with” [no.07]. These accounts are informed by the personal and
collective experiences of illness and deterioration. However, not all patients respond to
mitochondrial disease in this way. The finding that differences exist along generational
lines is critical when thinking about the target population for reproductive technologies.
Genetic technologies have the potential to create new patient populations by separat-
ing the diagnostic process from experiential awareness of symptoms. ‘Patients without
symptoms’ (Finkler et al. 2003) include those ‘at risk’ of developing a late onset condi-
tion (in the case of Huntington disease for example) and carriers of a genetic disorder
(in the case of recessive disorders such as cystic fibrosis or X-linked disorders such as
haemophilia). Mitochondrial disease fits both these categories of patient-hood in which
case an individual with or without symptoms might not consider themselves to be a
‘patient’. Through participant accounts, a picture emerges of a younger generation of
adults with experiences very different from those of their parents or grandparents. This
is not surprising given the late onset degenerative nature of the disease. However,
highlighting the experiences of disease and identifying differences according to gener-
ation sheds light on potentially diverse responses to reproductive risk.
Overwhelmingly, for most participants the diagnosis of mitochondrial disease did not
appear to be problematic. One reason for this appears to be the normalisation of symp-
toms and illness experiences. Mitochondrial disease is associated with an extensive
range of symptoms, some of which appear in childhood and become accepted as ‘nor-
mal’. All the participants were adults when they received a diagnosis. In addition, the
normalisation of illness appears to be facilitated when the illness is known within the
family. Many participants were diagnosed at the same time as others in the family, or
were aware that others in the family had already been diagnosed. Diagnosis therefore
does not necessarily mark the beginning of the patient journey nor lead to biographical
disruption (Bury 1982). This was the case for one woman who had received her diagno-
sis when she was nineteen years old, reflecting, “I knew there was this thing within the
family and it was making the people poorly, and it was genetic, but that was it, I didn’t
really take much interest in it” [no.16]. Readiness to receive and assimilate health infor-
mation is dependent on many factors including age and life stage (Gregory et al. 2007).
Thus for a generation of adults who might be relatively asymptomatic, and who are not
currently thinking about their reproductive future, the diagnosis of a genetic disease
does not necessarily trigger the search for technological intervention.
Whereas normalisation of symptoms and experiences might reduce the impact of
diagnosis for some, others identified how the nature of the disease led to disengage-
ment. A serious and life limiting disorder with limited treatment options is a potent
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to attend the specialist mitochondrial disease clinic or seek medical attention.
Because I keep saying to my sons, do you want to go and have the test for it? And they
say, well, what’s the point if there’s no cure? What can we do about it? There isn’t a
tablet that you can say, take this and it’ll make you better. [no.14, woman, age 56].
In describing her adult sons’ reluctance to seek confirmation of their own health status
or risk to health, this mother identifies the tension inherent within genetic medicine, the
separation of biomedical knowledge from experience. Mitochondrial disease is unusual as
a genetic disease because of the complex pattern of mitochondrial inheritance. All the off-
spring of a woman with mitochondrial disease will inherit a degree of defective mitochon-
dria but a blood test or muscle biopsy might identify the specific nature and extent of
mitochondrial dysfunction. Compared to single gene disorders, this challenges the bound-
aries between health, illness and being ‘at risk’. However, with the dearth of research ex-
ploring patient responses to mitochondrial disease, useful comparisons can be drawn with
other late onset conditions such as Huntington’s Disease, where the profound social and
emotional effects are better explored (Richards 2004) and where the uptake of
presymptomatic testing is low (Evers-Kiebooms et al. 2002). The availability of treatment
for disease is an important consideration in understanding the ways in which individuals
respond to genetic knowledge. The mother’s words suggesting her persistence in encour-
aging her sons to be tested, highlight a potential tension between current and future
health needs, the right ‘not to know’ and the range of actors with investment in these deci-
sions. In recognition of the limitations of current genetic knowledge, some participants
expressed a strong desire to offer protection to their adult children.
[Son] did come to an information event with us, only one, he hasn’t been back. [. . .]
He’ll make a point of saying I don’t want it and I don’t want to talk about it [. . .] He’s
young, he’s fit, he wants to get on with his life. And I don’t take that away from him
and his cousins because to me that’s what they need to do because looking back all I
can remember was my mother being bad, and then seeing my brothers and sisters,
and you think, well this is all I ever know is someone being bad in the family. [no.26,
woman age 52]
Many participants recognised why their children might not want to identify with an
illness identity, sanctioning the decision to ‘get on with life’. The protection afforded to
offspring is not just about shielding them from personal experience of illness but it also
involves protecting this generation from the family experience of illness. For this
mother it was important to know that her son, nieces and nephews would not share
the experience of caring for others. We know that women are the key communicators
of genetic knowledge within the family (Richards 1996), even undergoing genetic test-
ing to provide risk information for others (d’Agincourt-Canning 2001). The gendering
of roles and responsibilities was in evidence in this study, potentially accentuated by
the maternal inheritance pattern of mitochondrial disease. When talking about their
younger relatives, many of the female participants performed the role of ‘kin keeper’
(Young & Willmott 1957) by encouraging their adult children, nieces and nephews to
prioritise their health. Some participants expressed concern that the disease was not
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barking mad, we’re looking to be ill and all this, even though she suffers a lot herself
with different problems” [no.07]. Whereas the rejection of an illness identity can be cast
as a choice in the context of a disease with limited options for treatment, this was not
always the case. For one mother, the explanation as to why her nephews and nieces re-
fused to attend clinic was “they reckon ignorance is bliss” [no.15]. Awareness of the
progressive nature of the disease was also evident, as one parent warned, “little do they
know it might be them in ten or twenty years time” [no.03].
Responses to diagnosis of disease or risk are informed by personal stocks of know-
ledge (Parsons & Atkinson 1992; Michie & Marteau 1996). The reasons why individuals
choose to distance themselves from the disease and specialist management are mul-
tiple, including the relevance of health and genetic information, ‘getting on with life’
and ‘ignorance is bliss’. However, these strategies might have serious implications. In
the following extract a mother describes taking her two year old daughter to hospital
following a bout ‘stiffness’, demonstrating considerable barriers to communication
about mitochondrial disease:
Interviewee: They look at you stupid in the hospital and you think well I’m not
bringing my daughter in here for no reason
Researcher: So did you mention mitochondria then?
Interviewee: No. Should I have? [. . .] Do you know I have mentioned it in the past and
I think because of the blankness I get and it doesn’t seem to, they don’t care anyway. I
could have mentioned it and it wouldn’t have made any difference. My mother says to
me, like when they put me on these tablets, did you mention mitochondria? And I said
well they know, I’ve mentioned it before and she said yes but did you mention it again?
And I think, well I’ve told them before and they didn’t really give a stuff then so I don’t
see any point in telling them again. [no.25, woman, age 24]
This respondent was diagnosed with mitochondrial disease alongside her mother,
aunts and sisters and during the interview she talked about fatigue and the difficulties
of a physically demanding job. This woman’s mother and aunt were interviewed and
the impact of the disease was also prominent in their accounts. Yet for this woman,
neither her own diagnosis of mitochondrial disease nor the child’s potential diagnosis
(the daughter is at risk due to the nature of maternal inheritance) was used as a re-
source to explain the signs of illness or to communicate potential explanations to hos-
pital staff. This example brings into sharp relief the ways in which knowledge of
mitochondrial disease might be translated by following generations, emphasising the
challenges that rare and complex disease presents for patients and health services.
Through describing their own experiences, and telling stories about sons, daughters,
nieces and nephews, this research has revealed a generation of adults with mitochondrial
disease who might be described as a hard to reach group. The tension between disen-
gaging or being shielded from the personal and collective experience of illness and con-
cern for current health suggests a key role for counsellors and clinicians in identifying
transgenerational communication patterns concerning health, illness and genetic risk.
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A genetic diagnosis has been described as a ‘double edged sword’ where “[genetic] ex-
planations have a double edge, for while they shift responsibility to DNA, they create a
new biological form of blaming – for the ‘flawed’ parents who pass on ‘bad genes’ , for
those who knowingly take genetic risks (Nelkin & Lindee 1995). The development of
techniques of mitochondria donation presents a pertinent opportunity to examine the
implications of diagnosis and reproductive risk for patients with mitochondrial disease.
The aetiology of mitochondrial disease is complex and clinical consequences vary
greatly, even between mother and child (Poulton et al. 2003). For many types of mito-
chondrial disease, a ‘grey zone’ exists where the risk of developing symptoms, the type of
symptoms and severity are difficult to estimate (Bredenoord et al. 2009) leading to difficul-
ties in assessing reproductive risk and predicting outcome (Bredenoord et al. 2010). How
patients and those ‘at risk’ approach reproductive technologies has been explored in mul-
tiple contexts, including single gene disorders, late onset disorders and more complex dis-
orders such as cancer (Decruyenaere et al. 2007; Myring et al. 2011; Ormondroyd et al.
2012). In contrast, there has been little reflection about the contexts within which repro-
ductive decisions might be made by those with mitochondrial disease.
Technologies such as pre-implantation genetic diagnosis and prenatal diagnosis
which are currently available offer women with mitochondrial disease the opportunity
to reduce their risk of having a child with the disease (Poulton et al. 2010). Few partici-
pants in this study had experience of using assisted reproductive technologies,
reflecting the low uptake of these technologies at the national level (Poulton &
Oakeshott 2012). In the context of limited research in this vital area, this final section
presents a valuable case study of one woman’s experience of using assisted reproductive
technology. This woman’s decision to use prenatal diagnostic technologies was trig-
gered by the sudden illness of a close family member. Specifically, this extract points to
the woman’s response and subsequent outcome following prenatal diagnosis:
It was a baby boy, but he had 68% mutation and my mother had a similar percentage
so I was able to compare what could happen to my baby. We then made the
decision [to abort] because I could see what my mother was like and also my wider
family [. . .] We would be bringing a baby into the world knowing that at some point
it wasn’t going to have its health so we walked away and we thought, as much as we
don’t want to do this, it is the right thing to do. It was not an easy decision to make,
and we discussed this with our whole family, everyone who is affected by this
mutation [. . .] Our final decision came down to me and my husband saying if our
eldest son ever says, well why did you not do anything with me, why did you bring
me into the world - simple because we didn’t know. We didn’t understand and we
didn’t realise what could happen. But with that baby, we couldn’t have done that. It
would have been purely selfish reasons as to have just said, well no actually we’re
still going to let him come into the world. [no.16, woman, age 33]
How individuals make sense of uncertainty and complexity is a pertinent question in
the context of reproductive options. This is a highly personal account of making deci-
sions on basis of prenatal diagnostic information, specifically the identification of a mu-
tation level of 68%. Recognition of multiple interpretations of biomedical information
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Risk analysis relies on techniques of classification, presenting possibly reductionist diag-
nostic categories which have the capacity to challenge and reconfigure existing bound-
aries between health and illness. Genetic diagnosis continues to involve complex levels
of clinical decision making, even where a genetic mutation has been identified
(Hedgecoe 2003; Miller et al. 2005; Whitmarsh et al. 2007). Mitochondrial disease as a
highly complex disease classification falls into this category, where the presence of mu-
tated mitochondria does not necessarily lead to a diagnosis of mitochondrial disease.
This single account is important because it reveals how biomedical information and
the diagnostic criteria of mutation ratio, can be interpreted. Whereas mutation ratio is
used as a signifier to measure and project severity of disease, this can only be made
meaningful in the context of concrete experience of the disease. For this woman, this
process involved identifying the closest match within the family and then making a de-
cision based on that family member’s current health. This account therefore highlights
the centrality of experiential (personal and familial) knowledge in reproductive decision
making. The matching of genotype (of the baby) with phenotype (of the living adult)
was possible because the mutation ratio of individuals in this family were known. But
this reflects a key issue within genetic medicine which is the ownership and disclosure
of personal and collective information. Should this information about the health status
of family members, which appears to be significant in informing the decision making
process, be disclosed if the potential parents do not already know? In addition, assess-
ment of reproductive risk allows informed reproductive choice (Ten Kate 2012) but it
also holds the potential to reveal unrequested information, including the woman’s own
mutation level, in which case concerns might be raised about presymptomatic testing
(Skirton et al. 2013).
Finally, and returning to the development of novel reproductive techniques, the evi-
dence submitted to the Nuffield Council on Bioethics (Nuffield Council on Bioethics
2012) suggests widespread support from patients and professionals. However it is clear
that we have a lot more to discover about the use of technologies in practice. Vital
questions remain about how mitochondrial disease is experienced, measured and com-
municated, including how mutation ratio combines with experience to provide estima-
tions of risk and projections of the future, how normative decisions are made about
acceptable levels of mitochondrial mutation and how the boundaries between normal
and pathological are negotiated by both patients, families and health professionals.Conclusion
Mitochondrial medicine represents a rapidly changing field with newly emerging tools
for diagnosis and risk assessment. This article raises questions about responses to risk,
communication of health information and the role of technological solutions in the
context of complex and uncertain biomedical knowledge. The extensive interest in
mitochondria donation shown by policy-makers, interest groups and the media high-
light the significant challenge to existing legal and ethical frameworks. It also reveals a
gap between the capabilities of health technologies and knowledge of the practical real-
ities of living with genetic disease. Except for a few key exceptions (Noorda et al. 2007;
Bredenoord et al. 2011) the implications of introducing new technologies into the clinic
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adults with mitochondrial disease, and builds on the limited literature addressing the
perspectives of patients and families. Primarily, the modest research that has been
conducted has focused on the parental experience, characterised as extremely stressful
(Kim et al. 2010; Read 2003) and one study conducted with a large family cohort of
adult patients identified the relationship between maternal inheritance, blame and re-
sponsibility (Featherstone et al. 2006).
The identification of a patient population who do not choose to attend specialist clinics
is an important finding. Clinical contact with those at risk is considered important for
early intervention for long term health (Schaefer et al. 2008) but it is also important to
ensure patient choice and activity in the promotion of informed decision making
(Decruyenaere et al. 2007). In combination with the maternal inheritance pattern of mito-
chondrial disease, this disease clearly lays different burdens on women than it does on
their male counterparts. The development of reproductive technologies highlights the
gendered impact of disease and its technologies (Chadwick 2009), potentially leading to
surveillance of sexuality and lifestyle of young women. Finally, genetic technology informs
a new concept of ‘responsible’ parentage where prior knowledge of risk appears significant
when negotiating responsibility and the potential for blame (Finkler 2000). How patients
and potential parents account for their use and non-use of reproductive technologies will
be a vital question for future research.
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